Attenuation of Signaling Pathways Stimulated by Pathologically Activated Fgf-receptor 2 Mutants Prevents Craniosynostosis.
From: Department of Pharmacology and Section of Comparative Medicine, Yale University School of Medicine, New Haven, CT 06520, USA.
Proceedings of the National Academy of Sciences of the United States of America
- Publish Date: Dec 2006
- ISSN: 0027-8424
- Volume: 103
- Issue: 49
- Pages: 18603-8
- Medium: Print
- Language: English
- Citation (JAMA): Eswarakumar V P, Ozcan F, Lew E D, et al. Attenuation of Signaling Pathways Stimulated by Pathologically Activated Fgf-receptor 2 Mutants Prevents Craniosynostosis.. Proc. Natl. Acad. Sci. U.S.A. Dec 2006;103:18603-8
Abstract
Craniosynostosis, the fusion of one or more of the sutures of the skull vault before the brain completes its growth, is a common (1 in 2,500 births) craniofacial abnormality, approximately 20% of which occurrences are caused by gain-of-function mutations in FGF receptors (FGFRs). We describe a genetic and pharmacological approach for the treatment of a murine model system of Crouzon-like craniosynostosis induced by a dominant mutation in Fgfr2c. Using genetically modified mice, we demonstrate that premature fusion of sutures mediated by Crouzon-like activated Fgfr2c mutant is prevented by attenuation of signaling pathways by selective uncoupling between the docking protein Frs2alpha and activated Fgfr2c, resulting in normal skull development. We also demonstrate that attenuation of Fgfr signaling in a calvaria organ culture with an Fgfr inhibitor prevents premature fusion of sutures without adversely affecting calvaria development. These experiments show that attenuation of FGFR signaling by pharmacological intervention could be applied for the treatment of craniosynostosis or other severe bone disorders caused by mutations in FGFRs that currently have no treatment.
Mesh Headings (Keywords): Animals, Craniofacial Dysostosis, Craniosynostoses, Gene Expression Regulation, Mice, Mutagenesis, Site-Directed, NIH 3T3 Cells, Receptor, Fibroblast Growth Factor, Type 2, Signal Transduction
Check for Full Text / PubMed Unique Identifier (PMID): 17132737
This abstract is part of PubMed, a service of the U.S. National Library of Medicine. PubMed includes more than 17 million citations from MEDLINE and other life science journals for biomedical articles. See Copyright and Disclaimers.
Linked medical terms appearing on this page are added by Healia to help readers find more information and are not part of the original PubMed document.
The data herein was last updated on July 8th, 2008 and may not reflect the most current and accurate data available from NLM.